Literature DB >> 17954357

Beneficial effects of statin therapy on survival in hypertensive patients with acute myocardial infarction: data from the RICO survey.

Pierre Sicard1, Marianne Zeller, Gilles Dentan, Yves Laurent, Claude Touzery, Isabelle L'huillier, Luc Janin-Manificat, Luc Lorgis, Jean-Claude Beer, Hamib Makki, Luc Rochette, Yves Cottin.   

Abstract

BACKGROUND: Randomized studies have shown a reduction in cardiovascular events associated with low doses of statin among hypertensive patients at only moderate cardiovascular risk. The hypothesis of the present study was that statin therapy initiated during hospitalization could improve the long-term outcome after acute myocardial infarction (MI) in hypertensive patients.
METHODS: From the French regional obserRvatoire des Infarctus de Côte d'Or (RICO) survey, 1076 patients with a history of hypertension, surviving acute MI were included. Patients on statin therapy initiated before their hospitalization were excluded from the study. Patients were categorized into two groups based on whether or not statin treatment was initiated during the hospital stay.
RESULTS: Patients in the statin group were younger (70 years [range, 58 to 77 years] v 75 years [range, 65 to 82 years], P < .001) and were more likely to have hypercholesterolemia (42% v 28 %, P < .001). No differences were observed between the two groups for LDL-cholesterol levels on admission. At 1-year follow-up, cardiovascular mortality and rehospitalization for heart failure were lower in the statin group (respectively, 5% v 15%, P < .001; 5% v 7%, P < .001). Multivariate analysis showed that statin therapy was associated with decreased mortality (hazard ratio [95% confidence interval; CI]: 0.58 [0.32-0.98], P = .035) independently of either hypercholesterolemia, the use of beta-blockers, angiotensin-converting enzyme inhibitors, or diuretics, but not with a decreased incidence of heart failure (hazard ratio [95% CI]: 0.88 [0.55-1.23], P = .152).
CONCLUSIONS: In this observational study, the long-term benefits of statin therapy initiated in-hospital in hypertensive patients after acute MI was demonstrated. These findings may have implications for treatment optimization of hypertensive patients in secondary prevention.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17954357     DOI: 10.1016/j.amjhyper.2007.05.006

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  4 in total

1.  Effects of rosuvastatin and atorvastatin on nonsustained ventricular tachycardia in patients with ST-elevation myocardial infarction: a retrospective analysis.

Authors:  Xianqing Hu; Jian Cheng; Chunjian Li
Journal:  Eur J Clin Pharmacol       Date:  2017-09-30       Impact factor: 2.953

2.  The therapeutic effect of rosuvastatin on cardiac remodelling from hypertrophy to fibrosis during the end-stage hypertension in rats.

Authors:  W B Zhang; Q J Du; H Li; A J Sun; Z H Qiu; C N Wu; G Zhao; H Gong; K Hu; Y Z Zou; J B Ge
Journal:  J Cell Mol Med       Date:  2012-09       Impact factor: 5.310

3.  Rosuvastatin-attenuated heart failure in aged spontaneously hypertensive rats via PKCα/β2 signal pathway.

Authors:  Zhaohui Qiu; Wenbin Zhang; Fan Fan; Hua Li; Chaoneng Wu; Yong Ye; Qijun Du; Zheng Li; Xiaona Hu; Gang Zhao; Aijun Sun; Zhijun Bao; Junbo Ge
Journal:  J Cell Mol Med       Date:  2012-12       Impact factor: 5.310

4.  Incomplete medication adherence of chronically ill patients in German primary care.

Authors:  Jakob Hüther; Alessa von Wolff; Dorit Stange; Martin Härter; Michael Baehr; Dorothee C Dartsch; Levente Kriston
Journal:  Patient Prefer Adherence       Date:  2013-03-22       Impact factor: 2.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.